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1. Introduction 
Longstanding inflammation of the colonic mucosa places patients with ulcerative colitis 
(UC) at increased risk for the development of colon cancer. As such, there has been 
significant research over the last 20 years into efforts to understand the natural history of 
neoplastic lesions in UC in order to modify this risk. This chapter will focus on the 
epidemiology of neoplasia in UC, the biology of IBD-associated cancer, outcomes after a 
diagnosis of a dysplastic lesion, as well as strategies for surveillance and chemoprevention.  
2. Epidemiology 
The majority of studies examining the development of cancer in IBD have demonstrated an 
increased risk for neoplasia in patients with long-standing UC (1-6). A 2001 meta-analysis 
involving 116 studies and over 50,000 patients calculated the cumulative risk of CRC in UC 
as 8.3% at 20 years and 18.4% at 30 years (7). However, two recent population based studies, 
one from Denmark and the other from Olmstead County in Minnesota, did not find a 
significant increase in risk (3, 8).  The discrepancy in results between these more recent 
studies and older analyses may be secondary to the effects of newer, more effective anti-
inflammatory agents for IBD or the implementation of surveillance programs and removal 
of colons with dysplastic lesions prior to the development of cancer.  
3. Risk factors 
It is postulated that cancer develops in patients with IBD secondary to prolonged 
inflammation. The evidence to support inflammation driving neoplastic transformation 
stems from studies demonstrating that patients with longer disease duration, extensive 
colitis, and uncontrolled inflammation are at increased risk for neoplastic changes.  Risk of 
colorectal cancer (CRC) development rises with increased interval from diagnosis of IBD-
associated colitis (2, 9). In fact, CRC is uncommon in patients who have had colitis for less 
than 7 years, and more commonly develops in patients who are diagnosed with IBD at a 
younger age (5, 7). Several studies have also demonstrated that cancer develops more 
frequently in those with an increased extent of colitis (2, 4). A Swedish population-based study 
using barium enemas quantified this risk by standardized incidence ratio as 1.7 for individuals 
with proctitis, 2.8 for those with left-sided colitis, and 14.8 for those with pancolitis (2).  
Two recent publications have established that severity of inflammation is associated with an 
increased risk for cancer in IBD. In a retrospective cohort from the St. Mark’s hospital, 
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severity of inflammation by histology was significantly associated with neoplasia in patients 
with extensive colitis (10). Interestingly, in this multivariate analysis only histologic 
inflammatory activity and not endoscopic inflammation was associated with neoplasia. A 
second retrospective study from Mt. Sinai hospital in New York confirmed severity of 
inflammation over time as a risk for neoplasia (11).  
Two other well-described risk factors for neoplastic development in IBD include a family 
history of colorectal cancer and a history of primary sclerosing cholangitis (PSC). Several 
retrospective analyses have reported that patients with IBD who develop neoplasia have an 
odds ratio between 2.3 and 5.0 for having a family history of CRC (5, 12-14). A large 
population-based cohort also demonstrated a relative risk for the development of neoplasia 
of 2.5 for patients with a family history of colon cancer (15). As in the case of sporadic colon 
cancer with positive family history, this association was stronger for patients with a first-
degree relative with CRC less than 50 years of age (15). Potentially, the most significant risk 
factor for neoplasia in patients with UC is a concomitant diagnosis of PSC. Although the 
reported frequency of neoplastic changes in this population varies among studies, patients 
with UC and PSC have consistently demonstrated a markedly increased risk for the 
development of both dysplasia and colon cancer compared to patients with UC without PSC 
(5, 16-20). The overall incidence of CRC in patients with UC and PSC was between 16% and 
25% in a Swedish population-based study after 10 years of disease duration (17). This risk of 
neoplastic changes in UC patients with PSC has also been noted to occur earlier in the 
disease course than UC patients without PSC.  
4. Definition of dysplasia 
In UC, the term dysplasia is defined as neoplastic changes confined to the colonic 
epithelium. Tissue that is positive for dysplasia is most commonly identified as either low 
grade (LGD) or high grade (HGD) (21). Dysplasia is also characterized based on its 
endoscopic appearance, and outcomes of progression to cancer are associated with this 
endoscopic classification. Historically, flat dysplasia has been defined as dysplasia identified 
only by histological and not endoscopic features. However, recent studies have 
demonstrated that most lesions classified as flat dysplasia were obtained from targeted 
biopsies of visible lesions (22, 23). Raised lesions that are not endoscopically resectable are 
termed dysplasia associated mass or lesion or DALMs. The term ALM (adenoma-like mass) 
refers to a raised, endoscopically resectable lesion that resembles a sporadic adenoma by 
endoscopic and histological characteristics.  
5. Biology of IBD-associated cancer 
Although initiating mechanisms of carcinogenesis in IBD remain unknown, neoplastic 
lesions likely result from a combination of genetic alterations and inflammatory mediators 
that activate cell-signaling pathways. These pathways in turn promote deregulations in 
growth and apoptosis. Several molecular changes occurring in IBD-CRC are similar to those 
seen in sporadic CRC. In contrast to solitary lesions in sporadic colon cancer, however, 
neoplastic lesions in IBD are often multifocal. This finding likely reflects the widespread 
field defects throughout the UC involved mucosa that increase the risk for neoplastic 
changes. Moreover, expression changes in coding and non-coding (microRNA) genes that 
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are seen in malignant transformation, also occur in chronic UC, further supporting this 
hypothesis (24-26).   
Genomic instability characterized by either chromosomal instability or microsatellite 
instability occurs in both sporadic and IBD-associated CRC. In fact, frequencies of these 
genetic abnormalities (chromosomal instability – 85%, microsatellite instability – 15%) are 
similar in IBD-CRC and sporadic CRC (27-30).  
Genetic changes in the tumor suppressor, p53, are believed to play an important role in the 
development of IBD-associated neoplasia.  Loss of heterozygosity and p53 mutations have 
both been reported in colons with IBD-associated neoplasia (31-33). It is believed that 
changes in p53 may occur prior to the development of dysplastic lesions in ‘at risk’ mucosa 
(32). Moreover, reactivity of p53 antibodies increase with histologic progression from UC 
patients without dysplasia to those with dysplasia and CRC (34). Positive p53 immunostaining 
can also occur prior to the development of dysplasia in chronic UC mucosa (35, 36). 
The WNT pathway is deregulated in IBD-associated cancer development as occurs in 
sporadic colorectal carcinogenesis. Similar to genetic changes in p53, it appears that up-
regulation of WNT signaling occurs early in UC-associated neoplastic progression (37). In 
addition to overexpression of proteins in the WNT signaling cascade, hypermethylation of 
WNT-suppressor genes in this pathway occur during neoplastic development in IBD (38). 
Such methylations could lead to silencing of tumor suppressor genes. In contrast to sporadic 
colon cancer, however, it appears that APC loss of function mutations play a less significant 
role in initiating WNT signaling (39-41). Increased mutations in the oncogene, K-ras, have 
also been described in IBD-associated colon cancer (31). However, the timing of K-ras 
mutations in neoplastic progression needs to be clarified in larger studies.  
In addition to genetic changes, previous studies in animal models of ulcerative colitis and 
colitis-associated colon cancer have demonstrated involvement of other key signaling 
pathways including the vitamin D receptor, NFκB, transforming growth factor beta  (TGFβ), 
cyclooxygenase-2 (COX2), toll-like receptor-4 (TLR4), and the epidermal growth factor 
receptor (EGFR). Several mouse studies have shown that active vitamin D or its analogues 
inhibit progression in murine models of inflammation-associated colitis (42, 43) 
Furthermore, one retrospective analysis identified decreased expression of VDR in IBD-
associated dysplastic lesions (44). NFκB controls a vast array of functions and is a master 
regulator of many pro-inflammatory cytokines including TNF-α and IL-1β. NFκB 
overexpression is known to contribute to both inflammation and malignant transformation 
in several cancers (45). NFκB has also been demonstrated to contribute to malignant 
transformation in a mouse model of inflammation-associated cancer (46). In the study by 
Greten et al, NFκB in epithelial cells was essential for survival signals, allowing mutant 
clones to expand, whereas NFκB in stromal cells increased cytokines and growth factors 
required for tumor growth (46). Furthermore, NFκB mediates TNF-α activation of cytidine 
deaminase in human colonic epithelial cells and colitis-associated cancers. Activation 
induced cytidine deaminase plays a critical role in physiological antibody diversification, 
but also contributes to malignant lymphocytic transformation (47). In addition to NFκB 
up-regulation, TLR4 overexpression occurs in colitis-associated colon cancer that 
enhances Cox-2 expression via an EGFR-dependent mechanism (48). Recent studies from 
our laboratory have demonstrated that EGFR signals were required for Cox-2 up-
regulation in this model (49). 
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6. Surveillance for IBD-associated neoplasia 
There are no randomized controlled trials investigating the mortality benefit of surveillance 
colonoscopy in patients with UC. The best evidence to support routine endoscopic 
surveillance comes from retrospective case-controlled studies. In a retrospective analysis of 
patients with CRC, Choi et al. reported that patients who underwent surveillance had a 
carcinoma detected at an earlier Dukes stage and improved 5-year survival rate (50). A 
second analysis by Lashner and colleagues found that in 186 patients with extensive UC 
who underwent surveillance, patients had an improved survival and delayed time to 
colectomy, although the decrease in mortality was not related to cancer free survival (51). A 
Swedish population-based nested case-control study examining patients who died from 
CRC reported that two of 40 patients with UC who had died from colon cancer had 
undergone at least one screening exam, compared to 18 of 102 controls with UC who did not 
die from colon cancer (52). Similar protective effects of surveillance were seen in a second 
retrospective cohort (13). In a Cochrane database analysis of these studies published in 2006, 
the authors concluded that there was indirect evidence that surveillance is likely to show a 
cost benefit and be effective in reducing the risk of death from IBD-associated CRC (53). 
The current standard of care recommended for the prevention of cancer in IBD is regular 
surveillance colonoscopy. The ability to prevent cancer with this strategy relies on the early 
detection of precancerous lesions.  Most strategies for early detection involve both random 
biopsies and targeted biopsies of suspicious lesions. The major challenge with this strategy is 
sampling error. With random biopsies, it has been estimated 33 biopsies are needed to exclude 
dysplasia with 90% certainty and 64 biopsies are need for a 95% certainty. Most 
gastroenterologists do not approach such numbers of biopsies during surveillance exams (54, 
55).  Several recent studies, however, indicate that the yield of targeted biopsies is much 
greater than random biopsies of the colon. One possible explanation for these findings was 
suggested by three recent retrospective analyses. These studies concluded that most dysplastic 
lesions can be visualized with white light colonoscopy (22, 23, 56).   
Recent experience with chromoendoscopy, however, has consistently shown superior 
detection of dysplastic lesions with super vital staining compared to uncontrasted white 
light examinations (57-61). Chromoendoscopy is typically done with either indigo carmine 
or methylene blue dye. In a recent meta-analysis of six studies, the difference in proportion 
of lesions detected by chromoendoscopy vs. white light only was 44% (62). 
Autofluorescence with narrow band imaging (NBI) has been suggested to improve detection 
of dysplastic lesions in UC as well, although studies testing the benefit of NBI compared to 
high definition colonoscopy have been inconclusive (63-65). 
Several recommendations have been published to guide surveillance strategies in patients 
with UC (66-69). The most recent consensus statement was released by the American 
Gastroenterological Association (AGA) and recommended initiating surveillance no later 
than 8 years of disease duration for patients with left-sided or pancolitis (69). During 
surveillance examinations, multiple biopsies should be obtained from each anatomic 
location in the colon. This statement included chromoendoscopy as a recommended 
alternative to random biopsies by endoscopists who have expertise with the technique. The 
AGA recommended repeat examinations every 1-3 years and to decrease the interval to 
every 1-2 years after 20 years of disease duration. For patients with PSC, surveillance exams 
should be performed at the time of diagnosis and then yearly thereafter, because of an 
increased risk earlier in the disease course.  
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7. Outcome after a diagnosis of dysplasia 
After a diagnosis of flat HGD, colectomy has been universally recommended because there 
is a significant risk of harboring a synchronous CRC.  One systematic review calculated this 
risk as 42% (70). A subsequent prospective analysis from St. Marks Hospital reported a 45% 
incidence of synchronous carcinomas in patients undergoing immediate colectomy after 
diagnosis of HGD (9). In this analysis, eight patients underwent surveillance.  Of these eight, 
one developed CRC and seven developed further dysplasia (6 HGD, 1 LGD) (9).  There 
appears to be a similar risk of development of cancer in patients with endoscopically 
unresectable DALMs (70, 71). Because of the high risk of CRC development, colectomy is 
warranted for any patient with a DALM or flat HGD.  
In contrast to HGD, the management of patients with IBD-associated indeterminate 
dysplasia (IND) or LGD remains controversial. Previous studies have varied in their 
reported rates of progression from low-grade lesions to advanced neoplasia from 16% to 
54% (9, 70, 72-76). The discrepancy in reported rates of progression to advanced neoplasia is 
likely secondary to the population heterogeneity of these studies. Within the classification of 
LGD, outcomes are different for flat dysplastic lesions and adenoma-like dysplastic lesions 
(ALMs). For patients who have an ALM in the absence of surrounding dysplasia, the risk of 
development of cancer appears to be minimal (77-79). For this reason, patients with 
polypoid lesions that resemble a sporadic adenoma without surrounding flat dysplasia can 
be managed with endoscopic resection and surveillance. Conversely, flat dysplastic lesions 
carry a higher risk of malignant progression and of harboring a synchronous CRC at the 
time of diagnosis (72, 74, 78). Total abdominal colectomy should be discussed with patients 
following a diagnosis of flat LGD. For patients with controlled disease who elect to undergo 
surveillance of flat LGD lesions, close follow up with endoscopic evaluations, initially at 3 to 
6 month intervals is warranted. 
Although neoplastic changes may develop in the pouch or in the anal transition zone, the 
risk of dysplasia appears to be low for patients with UC who undergo a restorative 
proctocolectomy with ileoanal anastomosis.  One large analysis of 23 observational studies 
and over 2000 patients estimated that only slightly more than 1% of patients have confirmed 
dysplasia in the pouch or anal transition zone at follow up (80).  A more recent analysis of 
over 3000 patients from the Cleveland Clinic reported the incidence of neoplasia to be 0.9%, 
1.3%, 1.9%, 4.2%, and 5.1% at 5, 10, 15, 20, and 25 years after surgery, respectively (81). In 
both these studies, the risk of neoplastic transformation was significantly higher in patients 
who had dysplasia or cancer as their indication for initial colectomy. Although there are no 
published guidelines for surveillance after restorative proctocolectomy, many clinicians 
recommend a surveillance program because there remains a risk of neoplastic transformation, 
albeit low.  It is postulated that performing a hand-sewn ileoanal anastomosis may decrease 
the risk of neoplasia. However, published studies have reported no difference between a 
stapled technique and hand-sewn anastomosis with mucosectomy (81, 82).  
8. Chemoprevention 
The primary goal of chemoprevention is to decrease the incidence of neoplastic lesions in 
those at increased risk. An effective chemopreventive agent offers the theoretical advantage 
over surveillance endoscopy alone by deceasing the frequency, cost, and risk of 
colonoscopy, as well as reducing need for colectomy. 
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The majority of studies examining chemopreventive agents in IBD have focused on the use 
of 5-aminosalicylates (5-ASA). There are several postulated mechanisms by which 5-ASA 
inhibits malignant transformation. These include inhibition of NFκB, increased apoptosis of 
mutant clones, decreased proliferation, and prevention of oxygen-radical induced DNA 
damage (83-85). A meta-analysis of nine case control studies examining the efficacy of 5-
ASA in preventing dysplasia or cancer revealed a pooled odds ratio of 0.51 (95% CI, 0.38-
0.69) (86). However, several studies that have been published subsequent to this meta-
analysis have not found a protective effect of 5-ASA therapy (87-90).  Taken together, data to 
support 5-ASA chemoprevention in IBD is inconclusive, likely due to the heterogeneity of 
individuals in these studies. Furthermore, it is not known what effect 5-ASA has on CRC 
risk in patients who have achieved mucosal healing with other therapies. 
The bile acid, ursodeoxycholic acid, has been used as a chemopreventive agent in UC 
patients with PSC.  In animal models, UDCA is protective against the development of colon 
cancer (91-94).  The mechanism of UDCA’s chemopreventive activity remains uncertain, 
although it is likely multifactorial (92, 94) There have been two retrospective analyses of 
UDCA in patients with UC and PSC with conflicting results (93, 95-97). In a randomized 
placebo-controlled trial of UDCA at the dose of 13-15mg/kg-body wt/day, the relative risk 
for dysplasia or cancer in the group receiving UDCA was 0.26 (95% CI, 0.06-0.92). However, 
a more recent randomized placebo-controlled trial examining high dose UDCA (28-30 
mg/kg-body wt/day) in UC patients with PSC found that patients taking UDCA had a 
higher risk of developing colorectal neoplasia (98). Currently, the American Association for 
the Study of Liver Diseases (AASLD) does not recommend UDCA for chemoprevention in 
patients with UC and PSC as larger prospective studies of low dose UDCA are needed to 
further evaluate this potential chemopreventive agent (99).  
Other chemopreventive agents that have been studied in IBD-associated colitis include folic 
acid, immunomodulators, and vitamin D. Although a recent analysis of thiopurines in IBD 
found their use to be protective, the majority of studies investigating the chemopreventive 
efficacy of immunomodulators have not shown a benefit (10, 75, 100, 101). While folic acid 
deficiency is associated with decreased risk of sporadic CRC in epidemiological studies and 
folic acid is protective of other malignancies, the studies examining folic acid in the 
chemoprevention of CRC in patients with IBD have not demonstrated a benefit (102-104). 
The data on chemoprevention with folic acid in IBD comes from small retrospective 
analyses that have failed to show a statistical difference in the risk of dysplasia (105, 106). 
Finally, vitamin D has shown chemopreventive efficacy in murine models of sporadic and 
inflammation-associated colon cancer (42, 43, 107). Although vitamin D supplementation 
has not been examined in humans with UC, decreased vitamin D receptor expression is seen 
in cancers of patients with IBD and vitamin D appears to be chemopreventive of human 
CRC in epidemiological studies (44, 108). For this reason, vitamin D might offer a potential 
benefit to patients with chronic UC, although there have been no controlled studies in an 
IBD population. 
9. Conclusion 
Patients with chronic ulcerative colitis are at increased risk for the development of colon 
cancer. Because of this risk, colonoscopic surveillance is recommended for early detection of 
precancerous lesions. Successful implementation of surveillance programs has likely limited 
the mortality from CRC in this high-risk population. The outcome after detection of 
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dysplastic lesions needs to be better defined in future studies as endoscopic imaging 
techniques improve our ability to detect early neoplastic changes.   Identification of effective 
chemopreventive agents against CRC development in UC could decrease the incidence and 
morbidity of colitis-associated neoplasia. To date, however, there is a lack of data to 
recommend the use of any specific chemopreventive agents in UC. Because of the cost and 
morbidity in the detection and treatment of neoplastic lesions in chronic UC, future research 
is urgently needed to identify efficacious, safe, and cost-effective chemopreventive agents 
and to establish clinical and biological predictors of dysplasia in order to tailor personalized 
surveillance strategies.  
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